CADL's outsized modeled analyst upside is weighed against a quality-floor breach, an inconsistent earnings track record, and elevated short interest reflecting the binary risk of a clinical-stage biotech.
Thesis pillars
- Large Analyst Upside↑Improving
- Quality Floor Breach→Stable
- High Short Interest Elevated Iv→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 12, 2026
Candel Therapeutics, Inc. (CADL) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.67: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality.
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to trigger a systemic, individualized anti-tumor immune response against cancer. Its lead candidate, aglatimagene besadenovec, met the primary endpoint in a... Read more
Sell if holding. Engine safety override at $8.67: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 3/7 gates (favorable risk/reward ratio, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: speculative.
About Candel Therapeutics, Inc.
About Candel Therapeutics, Inc.
Candel Therapeutics has no products approved for commercial sale, so its most advanced candidate, aglatimagene besadenovec, an off-the-shelf adenoviral immunotherapy administered with valacyclovir, anchors the company's near-term value. In December 2024, the company reported that a 745-patient Phase 3 trial in newly diagnosed, localized prostate cancer met its primary endpoint for disease-free survival, and Candel plans to submit a Biologics License Application in the fourth quarter of 2026.
Candel's second platform candidate, linoserpaturev, an HSV-based immunotherapy, is being evaluated in an investigator-sponsored Phase 1b trial for recurrent high-grade glioma, with updated overall-survival data expected in 2026; the company also paused further development of aglatimagene in pancreatic cancer in October 2025 pending external funding, following positive but small-sample survival data. Both product candidates depend on third-party contract manufacturers for commercial-scale production, and Candel intends to build a largely externalized commercialization model around leading investigators, high-volume treatment centers and payers rather than a large internal sales force. The company funds operations partly through a $130 million term loan facility with Trinity, of which $50 million was drawn as of the filing, and a February 2026 equity offering that raised approximately $93.5 million.
Show full overview
Candel's near-term prospects are concentrated in a single pivotal readout: the aglatimagene prostate cancer Phase 3 data, generated under a Special Protocol Assessment with the FDA and supported by a May 2025 Regenerative Medicine Advanced Therapy designation, underpins the planned fourth-quarter-2026 BLA submission. A negative FDA review outcome, a delay in that submission, or an inability to replicate the trial's disease-free-survival benefit in real-world use would remove the company's clearest near-term path to any product revenue, since linoserpaturev remains in early-stage investigator-sponsored testing and the pancreatic cancer program for aglatimagene was paused in October 2025.
See also: Healthcare · Biotechnology
From Candel Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Candel Therapeutics, Inc.
Latest news
- NEWS Candel Therapeutics to Present at November Investor Conferences — fiscal.ai Oct 27, 2026 neutral
- NEWS Jefferies Initiates Coverage on Candel Therapeutics with Buy Rating — fiscal.ai Oct 23, 2026 positive
- NEWS Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $25 — benzinga Oct 22, 2026 positive
- NEWS Candel Therapeutics Appoints Maria Ostrovsky as General Counsel — fiscal.ai Oct 22, 2026 neutral
- NEWS Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients W — benzinga Oct 1, 2026 positive
Generated 2026-10-29T11:14:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineaglatimagene10-K Item 1: 'Our most advanced product candidate, aglatimagene besadenovec (referred to herein as aglatimagene and previously as CAN-2409), is an off-the-shelf adenovirus product candidate'
- MEDIUMSupplierthird party contract manufacturers10-K Item 1: 'We will rely on third party contract manufacturers for commercial-scale manufacturing of both product candidates, aglatimagene and linoserpaturev.'
Material Events(8-K, last 90d)
- 2026-06-16Item 5.02LOWCFO Charles Schoch entered into a new employment agreement effective June 12, 2026, continuing his at-will employment at an annual base salary of $468,600 with a 40%-of-salary target bonus. Not a departure; routine compensatory arrangement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.67: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 9.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $8.06. Score 5.0/10, moderate confidence.
Analyst target: $19.24 (+121.9% upside). Prior stop was $8.06. Stop-loss: $8.06.
Concentration risk — Pipeline: aglatimagene; Quality below floor (1.5 < 4.0).
Candel Therapeutics, Inc. trades at a P/E of N/A (forward -13.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover CADL with a consensus score of 4.3/5. Average price target: $22.
What does Candel Therapeutics, Inc. do?Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies...
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to trigger a systemic, individualized anti-tumor immune response against cancer. Its lead candidate, aglatimagene besadenovec, met the primary endpoint in a Phase 3 trial in localized prostate cancer reported in December 2024, with a Biologics License Application submission planned for the fourth quarter of 2026, while its HSV-based candidate linoserpaturev is in Phase 1b development for recurrent high-grade glioma. The company has not generated product revenue and relies o